New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
09:02 EDTBAXBaxter to acquire Chatham Therapeutics
Baxter International and Chatham Therapeutics announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Under the terms of the agreement, Baxter will make an initial payment of $70M to acquire all of the outstanding membership interests of Chatham. Baxter may make additional payments in the future based on specified development, regulatory and commercial milestones. Baxter will continue the ongoing Phase I/II open-label clinical trial to assess the safety and optimal dosing schedule of BAX 335, an investigational FIX gene therapy treatment for hemophilia B. The BNP technology provides a mechanism for the patient's own liver to begin producing FIX following a single dose of the genetically engineered treatment. The design of the vector allows for more targeted delivery of the FIX therapeutic “cargo” into the natural site of FIX synthesis. This may permit effective therapy with low quantities of the vector. The Phase I/II clinical trial is proceeding as expected and aims to enroll up to 16 hemophilia B patients. Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical on the development of novel hemophilia therapeutic gene therapy candidates using the Biological Nano Particle platform. AskBio is involved with the development of its proprietary BNPTM gene-delivery platform technology for therapeutics targeting diseases in the heart, CNS, muscle, ocular and liver tissues.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
09:05 EDTBAXBaxter files for European approval of investigational IGSC 20% treatment for PI
Baxter International announced that its BioScience business has submitted a marketing authorization application to 17 competent authorities in Europe following the decentralized procedure for approval of its investigational 20% concentration subcutaneous immune globulin, or IGSC, treatment for primary immunodeficiencies, or PI, a group of disorders in which part of the body's immune system is missing or does not function properly. Results from a separate study of IGSC 20% among patients with PI in North America are expected to be available in the coming months; based on the outcome of this study, Baxter intends to file for U.S. approval of the treatment before the end of 2015.
06:38 EDTBAXNovo Nordisk rejects claims made by Baxter, Reuters says
Novo Nordisk (NVO) rejects claims made by Baxter (BAX) that the company used substances made by Baxter in its Novoeight haemophilia treatment, following Monday's ITC investigation announcement, reports Reuters, citing an email from Novo Nordisk. Reference Link
May 18, 2015
12:24 EDTBAXBaxter sees FY16 sales growth 2%-3%
Subscribe for More Information
12:20 EDTBAXBaxter sees 2H sales growth approximately flat in constant currency
Subscribe for More Information
08:39 EDTBAXBaxter says Baxalta separation on-track for mid-year 2015
Subscribe for More Information
May 15, 2015
17:31 EDTBAXBaxter gets FDA approval for Spain facility to produce Sodium Chloride Injection
Subscribe for More Information
May 13, 2015
10:40 EDTBAXBaxter to host two day investor meeting
Two day Investor meeting to be held in New York May 18-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use